...
首页> 外文期刊>Nature clinical practice:Urology >Neoadjuvant chemotherapy for the treatment of muscle-invasive bladder cancer: argument in favor.
【24h】

Neoadjuvant chemotherapy for the treatment of muscle-invasive bladder cancer: argument in favor.

机译:新辅助化疗治疗肌肉浸润性膀胱癌:赞成。

获取原文
获取原文并翻译 | 示例
           

摘要

Remarkable improvements in surgical management of muscle-invasive bladder cancer have occurred in the past 20 years, with advances in continent urinary diversion, lymphadenectomy and perioperative care among the most noteworthy. Prognosis is inversely related to T-stage, with 20-30% of patients with T2 disease, but 70-90% with T4 disease, developing metastaticdisease after surgery alone. Node-positive patients have the worst survival. Thus, multi-disciplinary efforts are necessary to improve patient survival.
机译:在过去的20年中,肌肉浸润性膀胱癌的手术管理有了显着改善,其中最引人注目的是大陆性尿路改道,淋巴结清扫术和围手术期护理。预后与T期成反比,T2期患者中有20%至30%,T4期患者中有70%至90%,仅在手术后发展转移性疾病。淋巴结阳性的患者生存最差。因此,需要多学科的努力来提高患者的生存率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号